COMPARISON

Icatibant vs Melanotan II

5 attributes held for at least one of the two. 5 differ. Each value carries the register it came from and the date that register was read.

Answer

Icatibant is authorised or registered in 10 and Melanotan II in 0 of the 10 registers read. Icatibant: highest phase Phase 3 (3 phase 3 trials, 0 with posted results). Melanotan II: No trial states a phase. 0 registered trials include both.

States no view on which is preferable, safer or more effective. Not medical advice.

IcatibantMelanotan II
Registered trials
differs
37
clinicaltrials.gov · 2026-10-03
26
clinicaltrials.gov · 2026-10-03
FDA label
differs
FDA-approved: SAJAZIR
openfda · 2026-10-03T17:23:44.062Z
Not checked
no record of "fdaLabel" for melanotan-ii
EU authorisation
differs
Authorised
ema · 2026-10-03
Nothing on record
ema read 2026-08-31
EU authorised on
differs
2008-07-11
ema · 2026-10-03
Not checked
no record of "authorisedOn" for melanotan-ii
ATC code
differs
B06AC02
ema · 2026-10-03
Not checked
no record of "atcCode" for melanotan-ii

SIDE EFFECTS

Most common side effects, each beside its own placebo

Side effectIcatibantplaceboMelanotan IIplacebo
Hereditary angioedema18.1%18.7%--
Headache10.1%6.7%--

Trial register Icatibant: 4 placebo-controlled trials; Melanotan II: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Icatibant side effects · Melanotan II side effects

LEGAL STATUS

Approval in each country read

CountryIcatibantMelanotan IIRegister
United StatesFDA-approvedNot on the registerRegulator FDA
European UnionAuthorisedNot on the registerRegulator EMA
United KingdomAuthorisedNot on the registerRegulator MHRA
CanadaAuthorisedNot on the registerRegulator Health Canada
AustraliaRegisteredStatus unknownRegulator TGA
SwitzerlandAuthorisedNot on the registerRegulator Swissmedic
BrazilRegistadoNot on the registerRegulator ANVISA
SerbiaAuthorisedNot on the registerRegulator ALIMS
SingaporeRegisteredNot on the registerRegulator HSA
TurkeyRuhsatliNot on the registerRegulator TITCK

Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.

WEEKLY

Register Watch, weekly

New trials, approvals and enforcement actions. One email a week.